DOCSLIB.ORG

© 2016 First Aid for the USMLE Step 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
© 2016 First Aid for the USMLE Step 1 Index A Abscess, 442 vs. aspirin, in pediatric patients, 446 Achondroplasia, 426 Abacavir, 184 Absence seizures, 494 free radical injury and, 221 autosomal dominance of, 71 for HIV, 186 drug therapy for, 500 necrosis caused by, 252 chromosome associated with, 75 Abciximab, 214, 407 treatments for, 638 for osteoarthritis, 430 endochondral ossification in, 425 thrombogenesis and, 385 Absolute risk reduction (ARR), 34, for tension headaches, 494 AChR (acetylcholine receptor), 229 Abdominal aorta, 342 646 toxicity effects, 446 Acid-base physiology, 543 atherosclerosis in, 286, 645 Absorption disorders, anemia caused toxicity treatment for, 251 Acidemia, 543 bifurcation of, 609 by, 388 Acetazolamide, 254, 557 diuretic effect on, 558 498 92 Abdominal aortic aneurysm, 286 Abuse for glaucoma, Acidic amino acids, metabolic acidosis caused by, 543 Acidosis, 543 Abdominal colic confidentiality exceptions and, 41 in nephron physiology, 537 contractility in, 267 lead poisoning as cause, 389 dependent personality disorder for pseudotumor cerebri, 471 hyperkalemia caused by, 542 Abdominal distension and, 519 site of action, 556 Acid phosphatase, in neutrophils, 378 duodenal atresia as cause, 338 Acalculia, 464 Acetoacetate, metabolism of, 102 Acid reflux Abdominal pain Acamprosate Acetone breath, in diabetic esophageal strictures and, 354 Budd-Chiari syndrome as for alcoholism, 523, 638 ketoacidosis, 331 esophagitis and, 354 cause, 368, 630 diarrhea caused by, 252 Acetylation, 57 H blockers for, 374 cilostazol/dipyridamole as Acanthocytes, 386 2 Acetylcholine (ACh), 455 proton pump inhibitors for, 374 cause, 407 Acanthocytosis, 81 in Alzheimer disease, 491, 511 sclerodermal esophageal Clostridium difficile as cause, 630 Acantholysis, 439 anticholinesterase effect on, 244 dysmotility as cause, 354 diabetic ketoacidosis as cause, 331 pemphigus vulgaris and, 443 in Huntington disease, 71, 462, 511 Acid suppression therapy, 374 ectopic pregnancy as cause, 589 Acanthosis, 439 in nervous system, 241 Acinetobacter spp., 168 Henoch-Schönlein purpura as psoriasis as cause, 440 opioid effect on, 499 Acinetobacter baumannii, 181 cause, 297, 633 Acanthosis nigricans, 229, 444 pacemaker action potential Acne, 440 542 acanthosis and, 439 hypercalcemia as cause, and, 275 danazol as cause, 602 stomach cancer as cause, 356 hyperparathyroidism as cause, 326 in Parkinson disease, 511 glucocorticoids as cause, 212 Acarbose, 335 intussusception as cause, 362 Acetylcholine (ACh) receptor PCOS as cause, 591 diarrhea caused by, 252 irritable bowel syndrome as agonists, 503 prednisone as cause, 412 Accessory nerve (11th cranial cause, 360 Acetylcholine (ACh) receptors, 241 as skin papules, 438 nerve), 479 McBurney sign as, 633 in cholinergic drugs, 243 tetracyclines for, 175 lesion in, 480 Meckel diverticulum as cause, 567 Acetylcholine (AChR) receptor, 229 Acoustic neuromas, 453 location in brain stem, 477 pancreas divisum as cause, 339 Acetylcholinesterase (AChE) Acoustic schwannomas, 71, 630 478 pancreatic cancer as cause, 373 pathway for, cholinesterase inhibitor Acquired hydroceles, 598 panic disorder as cause, 517 Accessory pancreatic duct, 339, 347 poisoning, 244 Acrodermatitis enteropathica, 82 polyarteritis nodosa as cause, 296 Accuracy vs. precision, 35 malathion and, 183 Acromegaly, 327 porphyria as cause, 395 Acebutolol, 249 neural tube defects and, 451 GH as cause, 311 Rovsing sign as, 633 angina and, 299 Acetylcholinesterase (AChE) octreotide for, 375 Abdominal wall, developmental ACE inhibitors, 559 inhibitors somatostatin analogs for, 309 defects in, 338 for acute coronary syndromes, 290 for Alzheimer disease, 505 somatostatin for, 336 Abducens nerve (6th cranial C1 esterase inhibitor deficiency in cholinergic drugs, 243 Acromion, 417 nerve), 479 and, 199 for myasthenia gravis, 436 ACTH. See Adrenocorticotropic location in brain stem, 477 for dilated cardiomyopathy, 291 naming convention for, 255 hormone (ACTH) ocular motility and, 488 dry cough caused by, 254 toxicity treatment for, 251 Actin filaments in epithelial cells, 438 palsy of, 489 for heart failure, 292 Acetyl-CoA carboxylase, 84 Acting out, as ego defense, 508 pathway for, 478 for hypertension, 298 vitamin B7 and, 79 Actinic keratosis, 444, 445 Abductor digiti minimi muscle, 421 naming convention for, 255 Achalasia, 354 key associations, 641 Abductor pollicis brevis muscle, 421 preload/afterload, effect on, 267 esophageal cancer and, 355 Actin, in cytoskeleton, 60 Abetalipoproteinemia, 386 as teratogens, 564 Achilles reflex, 476 Actinomyces spp. Abnormal passive abduction, 416 Acetaldehyde dehydrogenase, in disc herniation and, 423 as anaerobic organism, 111 Abnormal passive adduction, 416 ethanol metabolism, 83 Achilles tendon xanthomas, 285, 630 in Gram-positive algorithm, 118 ABO blood classification, 382 Acetaldehyde, in ethanol Achlorhydria morphology of, 109 ABO hemolytic disease of the metabolism, 83 stomach cancer and, 356 vs. Nocardia spp., 123 newborn, 382 Acetaminophen, 446 VIPomas as cause, 350 penicillin G/V for, 170 © 2016 First Aid for the USMLE Step 1 NTC_FAS1_2016_24_Index_687-760.indd 687 11/3/15 4:53 PM 688 INDEX INDEX Actinomyces israelii Acute renal failure, 553 in electron transport chain, 89 Adult T cell leukemia, 231 branching rods in, 169 Acute respiratory distress syndrome expenditure vs. time, 103 Adult T-cell lymphoma, 400 lab findings in, 635 (ARDS), 621 in glycogen regulation, 97 Advance directives, 41 pigment produced by, 113 acute pancreatitis as cause, 373 in nephron physiology, 537 Aedes mosquitoes, yellow fever Action/willpower stage of overcoming eclampsia as cause, 590 production of, 86 transmitted, by, 152 addiction, 521 as inhalational injury, 222 in TCA cycle, 88 Aerobic metabolism, 103 Activated carriers, 86 as restrictive lung disease, 619 in urea cycle, 93 Aerobic organisms, 111 Active errors, 46 Acute stress disorder, 517 Adenosine triphosphate (ATP) Afferent arteriole, 532 Active immunity, 203 Acute transplant rejection, 211 synthase inhibitors, 89 ANP/BNP effect on, 540 Acute chest syndrome, 392 Acute tubular necrosis, 554 Adenoviruses constriction of, 535 Acute cholestatic hepatitis granular casts in, 544 characteristics of, 148 dopamine, effect on, 541 as drug reaction, 252 intrinsic renal failure caused conjunctivitis caused by, 484 in filtration, 535 macrolides as cause, 176 by, 553 as DNA viruses, 147 Afferent nerves, 279 Acute closure, 484 Acyclovir, 184 as naked viruses, 147 Aflatoxin Acute coronary syndrome Adalimumab, 214, 448 pneumonia caused by, 624 as carcinogens, 231 ADP receptor inhibitors for, 407 for Crohn disease, 359 watery diarrhea caused by, 162 hepatocellular carcinoma heparin for, 405 Adaptive immunity, 192 Adherens junctions, 438 and, 368 nitrates for, 299 Addison disease, 318 Adhesion, 362 Aflatoxins, 137 treatments for, 290 metabolic acidosis caused by, 543 Adipose lipolysis, 300 African sleeping sickness, 140 Acute cystitis, 544 presentation of, 633 Adipose stores, in fasting/starvation Afterload, in cardiac output, 267 Acute disseminated Additive drug interactions, 237 states, 103 Agammaglobulinemia encephalomyelitis, 493 Adductor longus muscle, 347 Adipose tissue, estrogen production chromosome associated with, 75 Acute dystonia, 245 Adenine by, 577 Agarose gel electrophoresis, 64 Acute gastritis, 356 methylation of, 48 Adjustment disorder, 517 Agars for bacterial culture, 111 Acute glomerulonephritis, 553 Shiga/Shiga-like toxins and, 116 Adoption studies, 32 Agenesis, 563 Acute hemolytic transfusion Adenocarcinomas ADP receptor inhibitors, 407 Age-related macular 206 carcinogens causing, 231 reactions, Adrenal adenomas degeneration, 485 as type II hypersensitivity of esophagus, 355 Cushing syndrome caused by, 317 Aggregatibacter reactions, 204 of gallbladder, 372 hyperaldosteronism caused by, 318 actinomycetemcomitans, 293 Acute hemorrhagic cystitis, 148 gastrointestinal, 229 Adrenal carcinomas Agnosia, in dementia, 513 Acute inflammation, 219 of lungs, 626 Cushing syndrome caused by, 317 Agonist potency and efficacy, 240 Acute inflammatory demyelinating nomenclature for, 228 P-glycoprotein in, 232 Agoraphobia, 517 polyradiculopathy, 493 nonbacterial thrombotic Adrenal cortex, 306 Agranulocytosis Acute intermittent porphyria, 395 endocarditis and, 229 embryologic derivatives of, 563 clozapine as cause, 525 Acute interstitial nephritis, 554 of pancreas, 373 progesterone production in, 577 as drug reaction, 252 Acute lymphoblastic leukemia pectinate line and, 345 Adrenal hemorrhage, 630 epilepsy drugs causing, 500 (ALL), 402 of prostate, 599 Waterhouse-Friderichsen syndrome sulfa drug allergies as cause, 254 key associations, 644 of stomach, 356, 645 and, 318 thionamides as cause, 335 methotrexate for, 409 Trousseau’s syndrome and, 229 Adrenal hyperplasia Agraphia, cause of, 464 oncogenes and, 230 Adenohypophysis, 307 Cushing syndrome caused by, 317 AIDS (acquired immunodeficiency Acute mesenteric ischemia, 362 embryologic derivatives of, 563 hyperaldosteronism and, 318 presentation of, 633 hypothalamus and, 456 syndrome) 318 Acute myeloid leukemia (AML), 402 Adenomas Adrenal insufficiency, bacillary angiomatosis and, 441 chromosomal translocations of adrenal cortex, 645 anovulation caused by, 591 diagnosis of, 158 and, 403 of bone, 428 fludrocortisone for, 336 marijuana as appetite stimulant cytarabine for, 409 colorectal, 364 glucocorticoids for, 336 in, 523 key associations, 644 hyperparathyroidism as cause, 645 vitamin B5 deficiency as cause, 78 opportunistic infections in, 644 myelodysplastic syndromes
Load more

Recommended publications
  • Pulmonary Cancer And/Or GPA? Diagnostic Implications of Pulmonary Nodules
    Gaceta Médica de México. 2016;152 Contents available at PubMed www.anmm.org.mx PERMANYER Gac Med Mex. 2016;152:468-74 www.permanyer.com GACETA MÉDICA DE MÉXICO ORIGINAL ARTICLE Pulmonary pseucotumor in granulomatosis with polyangiitis (GPA). Pulmonary cancer and/or GPA? Diagnostic implications of pulmonary nodules Gabriel Horta-Baas1*, Esteban Meza-Zempoaltecatl2, Mario Pérez-Cristóbal2 and Barile-Fabris Leonor Adriana2 1Rheumatology Department, Hospital General Regional 220, IMSS, Toluca; 2Rheumatology Department, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, IMSS, Mexico City, Mexico Abstract Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis, is a systemic necrotizing vasculitis, which affects small and medium sized blood vessels and is often associated with cytoplasmic anti-neutrophil cytoplasmic antibodies (ANCA). Inflammatory pseudotumor is a rare condition characterized by the appearance of a mass lesion that mimics a malignant tumor both clinically and on imaging studies, but that is thought to have an inflammatory/reactive pathogenesis. We report a patient with a GPA which was originally diagnosed as malignancy. (Gac Med Mex. 2016;152:468-74) Corresponding author: Gabriel Horta-Baas, [email protected] KEY WORDS: Granulomatosis with polyangiitis. Pseudotumor. Malignancy. Introduction Presentation of the case According to the 2012 revised Chapel Hill classifica- This is the case of a 39-year old male who was tion, granulomatosis with polyangiitis (GPA), previously admitted in the hospital presenting with asthenia, gen- known as Wegener’s granulomatosis (WG), is an auto- eral malaise, intermittent fever (3 to 4 times a month), immune systemic disease of unknown etiology, charac- diaphoresis with no time of day predominance and loss terized by necrotizing granulomatous inflammation of the of 10-kg weight in 6 months.
    [Show full text]
  • Print Your Symptom Diary
    MEDICATION GUIDE FETZIMA® (fet-ZEE-muh) (levomilnacipran) extended-release capsules, for oral use What is the most important information I should know about FETZIMA? FETZIMA may cause serious side effects, including: • Increased risk of suicidal thoughts or actions in some children, adolescents, and young adults. FETZIMA and other antidepressant medicines may increase suicidal thoughts or actions in some children and young adults, especially within the first few months of treatment or when the dose is changed. FETZIMA is not for use in children. o Depression or other serious mental illnesses are the most important causes of suicidal thoughts or actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have (or have a family history of) depression, bipolar illness (also called manic-depressive illness) or have a history of suicidal thoughts or actions. How can I watch for and try to prevent suicidal thoughts and actions? o Pay close attention to any changes, especially sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions. This is very important when an antidepressant medicine is started or when the dose is changed. o Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. o Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms. Call your healthcare provider or
    [Show full text]
  • © 2019 First Aid for the USMLE Step 1 732 INDEX INDEX
    Index A Abnormal uterine bleeding (AUB), heart failure, 306 Achondroplasia, 454 A-a gradient 618, 619 hypertension, 312 chromosome disorder, 64 in elderly, 654 adenomyosis, 634 naming convention for, 253 endochondral ossification in, 450 with hypoxemia, 654, 655 anemia with, 410 preload/afterload effects, 282 inheritance, 60 restrictive lung disease, 661 Asherman syndrome, 634 teratogenicity, 600 AChR (acetylcholine receptor), 229 Abacavir, 201, 203 leiomyoma (fibroid), 634 Acetaldehyde, 72 Acid-base physiology, 580 Abciximab, 122 polyps (endometrial), 634 Acetaldehyde dehydrogenase, 70, 72 Acidemia, 580 Glycoprotein IIb/IIIa inhibitors, thecoma, 632 Acetaminophen, 474 diuretic effect on, 595 429 ABO blood classification, 397 vs. aspirin for pediatric patients, 474 Acid-fast oocysts, 177 thrombogenesis and, 403 newborn hemolysis, 397 free radical injury and, 210 Acid-fast organisms, 125, 140, 155 Abdominal aorta, 357 Abruptio placentae, 626 hepatic necrosis from, 249 Acidic amino acids, 81 atherosclerosis in, 300, 687 cocaine use, 600 N-acetylcysteine for overdose, 671 Acid maltase, 86 bifurcation of, 649 preeclampsia, 629 for osteoarthritis, 458 Acidosis, 578, 580 Abdominal aortic aneurysm, 300 Abscess, 470 toxicity effects, 474 contractility in, 282 Abdominal colic acute inflammation and, 215 toxicity treatment for, 247 hyperkalemia with, 578 lead poisoning, 411 lung, 670 Acetazolamide, 252, 539, 594 Acid phosphatase in neutrophils, 398 Abdominal pain Absence seizures idiopathic intracranial Acid reflux bacterial peritonitis, 384 characteristics
    [Show full text]
  • Rhinotillexomania in a Cystic Fibrosis Patient Resulting in Septal Perforation Mark Gelpi1*, Emily N Ahadizadeh1,2, Brian D’Anzaa1 and Kenneth Rodriguez1
    ISSN: 2572-4193 Gelpi et al. J Otolaryngol Rhinol 2018, 4:036 DOI: 10.23937/2572-4193.1510036 Volume 4 | Issue 1 Journal of Open Access Otolaryngology and Rhinology CASE REPORT Rhinotillexomania in a Cystic Fibrosis Patient Resulting in Septal Perforation Mark Gelpi1*, Emily N Ahadizadeh1,2, Brian D’Anzaa1 and Kenneth Rodriguez1 1 Check for University Hospitals Cleveland Medical Center, USA updates 2Case Western Reserve University School of Medicine, USA *Corresponding author: Mark Gelpi, MD, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106, USA, Tel: (216)-844-8433, Fax: (216)-201-4479, E-mail: [email protected] paranasal sinuses [1,4]. Nasal symptoms in CF patients Abstract occur early, manifesting between 5-14 years of age, and Cystic fibrosis (CF) is a multisystem disease that can have represent a life-long problem in this population [5]. Pa- significant sinonasal manifestations. Viscous secretions are one of several factors in CF that result in chronic sinona- tients with CF can develop thick nasal secretions con- sal pathology, such as sinusitis, polyposis, congestion, and tributing to chronic rhinosinusitis (CRS), nasal conges- obstructive crusting. Persistent discomfort and nasal man- tion, nasal polyposis, headaches, and hyposmia [6-8]. ifestations of this disease significantly affect quality of life. Sinonasal symptoms of CF are managed medically with Digital manipulation and removal of crusting by the patient in an attempt to alleviate the discomfort can have unfore- topical agents and antibiotics, however surgery can be seen damaging consequences. We present one such case warranted due to the chronic and refractory nature of and investigate other cases of septal damage secondary to the symptoms, with 20-25% of CF patients undergoing digital trauma, as well as discuss the importance of sinona- sinus surgery in their lifetime [8].
    [Show full text]
  • Levomilnacipran (Fetzima®) Indication
    Levomilnacipran (Fetzima®) Indication: Indicated for the treatment of major depressive disorder (MDD), FDA approved July 2013. Mechanism of action Levomilnacipran, the more active enantiomer of racemic milnacipran, is a selective SNRI with greater potency for inhibition of norepinephrine relative to serotonin reuptake Compared with duloxetine or venlafaxine, levomilnacipran has over 10-fold higher selectivity for norepinephrine relative to serotonin reuptake inhibition The exact mechanism of the antidepressant action of levomilnacipran is unknown Dosage and administration Initial: 20 mg once daily for 2 days and then increased to 40 mg once daily. The dosage can be increased by increments of 40 mg at intervals of two or more days Maintenance: 40-120 mg once daily with or without food. Fetzima should be swallowed whole (capsule should not be opened or crushed) Levomilnacipran and its metabolites are eliminated primarily by renal excretion o Renal impairment Dosing: Clcr 30-59 mL/minute: 80 mg once daily Clcr 15-29 mL/minute: 40 mg once daily End-stage renal disease (ESRD): Not recommended Discontinuing treatment: Gradually taper dose, if intolerable withdrawal symptoms occur, consider resuming the previous dose and/or decrease dose at a more gradual rate How supplied: Capsule ER 24 Hour Fetzima Titration: 20 & 40 mg (28 ea) Fetzima: 20 mg, 40 mg, 80 mg, 120 mg Warnings and Precautions Elevated Blood Pressure and Heart Rate: measure heart rate and blood pressure prior to initiating treatment and periodically throughout treatment Narrow-angle glaucoma: may cause mydriasis. Use caution in patients with controlled narrow- angle glaucoma Urinary hesitancy or retention: advise patient to report symptoms of urinary difficulty Discontinuation Syndrome Seizure disorders: Use caution with a previous seizure disorder (not systematically evaluated) Risk of Serotonin syndrome when taken alone or co-administered with other serotonergic agents (including triptans, tricyclics, fentanyl, lithium, tramadol, tryptophan, buspirone, and St.
    [Show full text]
  • Levomilnacipran for the Treatment of Major Depressive Disorder
    Out of the Pipeline Levomilnacipran for the treatment of major depressive disorder Matthew Macaluso, DO, Hala Kazanchi, MD, and Vikram Malhotra, MD An SNRI with n July 2013, the FDA approved levomil- Table 1 once-daily dosing, nacipran for the treatment of major de- Levomilnacipran: Fast facts levomilnacipran pressive disorder (MDD) in adults.1 It is I Brand name: Fetzima decreased core available in a once-daily, extended-release formulation (Table 1).1 The drug is the fifth Class: Serotonin-norepinephrine reuptake symptoms of inhibitor serotonin-norepinephrine reuptake inhibi- MDD and was well Indication: Treatment of major depressive tor (SNRI) to be sold in the United States disorder in adults tolerated in clinical and the fourth to receive FDA approval for FDA approval date: July 26, 2013 trials treating MDD. Availability date: Fourth quarter of 2013 Levomilnacipran is believed to be the Manufacturer: Forest Pharmaceuticals more active enantiomer of milnacipran, Dosage forms: Extended–release capsules in which has been available in Europe for 20 mg, 40 mg, 80 mg, and 120 mg strengths years and was approved by the FDA in Recommended dosage: 40 mg to 120 mg 2009 for treating fibromyalgia. Efficacy of capsule once daily with or without food levomilnacipran for treating patients with Source: Reference 1 MDD was established in three 8-week ran- domized controlled trials (RCTs).1 cial and occupational functioning in addi- Clinical implications tion to improvement in the core symptoms Levomilnacipran is indicated for treating of depression.5
    [Show full text]
  • Premium Non-Specialty Quantity Limit List January 2016
    Premium Non-Specialty Quantity Limit List January 2016 Therapeutic Category Drug Name Dispensing Limit Anti-infectives Antibiotics DIFICID (fidaxomicin) 200 mg 2 tabs/day & 10 days/30 days SIVEXTRO (tedizolid) Solr 6 vials/30 days SIVEXTRO (tedizolid) Tabs 6 tabs/30 days ZYVOX (linezolid) 28 tabs/30 days ZYVOX (linezolid) Suspension 4 bottles (600 mL)/28 days Antifungals LAMISIL (terbinafine) 250 mg 84 days supply/180 days Antimalarial QUALAQUIN (quinine) QL varies* Antivirals, Herpetic FAMVIR (famciclovir) 125 mg 1 tab/day FAMVIR (famciclovir) 250 mg 2 tabs/day FAMVIR (famciclovir) 500 mg 21 tabs/30 days SITAVIG (acyclovir) 50 mg 2 tabs/30 days VALTREX (valacyclovir) 1000 mg 3 tabs/day VALTREX (valacyclovir) 500 mg 2 tabs/day Antivirals, Influenza RELENZA (zanamivir) QL is 40 inh per 365 days. TAMIFLU (oseltamivir) 30 mg 40 caps per 365 days TAMIFLU (oseltamivir) 45 mg, 75 mg 20 caps per 365 days TAMIFLU (oseltamivir) Suspension 360 mL/365 days Cardiology Anticoagulants ELIQUIS (apixiban) 2 tabs/day ELIQUIS (apixiban) 5 mg 3 tabs/day IPRIVASK (desirudin) 35 days supply/180 days PRADAXA (dabigatran) 2 caps/day SAVAYSA (edoxaban) 1 tab/day XARELTO (rivaroxaban) 10 mg 35 days supply/180 days XARELTO (rivaroxaban) 15 mg 2 tabs/day XARELTO (rivaroxaban) 20 mg 1 tab/day XARELTO (rivaroxaban) Starter Pack 2 starter packs/year Heart Failure CORLANOR (ivabradine) 2 tabs/day Central Nervous System ADHD Agents ADDERALL (amphetamine/dextroamphetamine) 3 tabs/day ADDERALL XR (amphetamine/dextroamphetamine mixed salts) 1 cap/day APTENSIO XR (methylphenidate)
    [Show full text]
  • Cytology of Myeloma Cells
    J Clin Pathol: first published as 10.1136/jcp.29.10.916 on 1 October 1976. Downloaded from J. clin. Path., 1976, 29, 916-922 Cytology of myeloma cells F. G. J. HAYHOE AND ZOFIA NEUMAN1 From the Department of Haematological Medicine, Cambridge University SYNOPSIS A cytological, cytochemical, and cytometric study of plasma cells from 195 cases of multiple myeloma showed that, contrary to earlier reports, flaming cells, thesaurocytes, and intra- nuclear inclusions are not confined to IgA-secreting cases but are common also in IgG and Bence Jones varieties of myeloma. IgA-secreting cells are not larger, nor do they have a lower nuclear- cytoplasmic ratio than other myeloma cells. On average, for a given mass of tumour, Bence-Jones, IgG, and IgA varieties of myeloma produce amounts of paraprotein in the ratio 1 to 1 6 to 2-7. In 1961 Paraskevas et al reported a correlation the results of a larger scale survey carried out some between the morphological features of plasma cells years ago but previously unpublished. in myeloma and the type of immunoglobulin secreted. The cases studied included 12 with y1A Material and methods (f2A, IgA) myeloma, 30 with y (IgG) myeloma, and six myelomas without M protein (probably Bence The study was performed on bone marrow smearscopyright. Jones myelomas). Flaming cells, thesaurocytes, and from 200 consecutive patients newly entered into a intranuclear, PAS-positive inclusion bodies were comparative trial of treatments in myeloma, under found only in cases of IgA myeloma, and flaming the auspices of the Medical Research Council. Five cells especially were present in most cases and in patients were subsequently excluded as not confirmed high percentage in several.
    [Show full text]
  • Ear-Nose-Throat Manifestations in Inflammatory Bowel Diseases ANNALS of GASTROENTEROLOGY 2007, 20(4):265-274X Xx 265X
    xx xx Ear-nose-throat manifestations in Inflammatory Bowel Diseases ANNALS OF GASTROENTEROLOGY 2007, 20(4):265-274x xx 265x Review Ear-nose-throat manifestations in Inflammatory Bowel Diseases C.D. Zois, K.H. Katsanos, E.V. Tsianos going activation of the innate immune system driven by SUMMARY the presence of luminal flora. Both UC and CD have a Inflammatory bowel diseases (IBD) refer to a group of chron- worldwide distribution and are common causes of mor- ic inflammatory disorders involving the gastrointestinal tract bidity in Western Europe and northern America. and are typically divided into two major disorders: Crohn’s The extraintestinal manifestasions of IBD, however, disease (CD) and ulcerative colitis (UC). CD is characterized are not of less importance. In some cases they are the first by noncontiguous chronic inflammation, often transmural clinical manifestation of the disease and may precede the with noncaseating granuloma formation. It can involve any onset of gastrointestinal symptoms by many years, playing portion of the alimentary tract and CD inflammation has of- also a very important role in disease morbidity. As multi- ten been described in the nose, mouth, larynx and esopha- systemic diseases, IBD, have been correlated with many gus in addition to the more common small bowel and colon other organs, including the skin, eyes, joints, bone, blood, sites. UC differs from CD in that it is characterized by con- kidney, liver and biliary tract. In addition, the inner ear, tiguous chronic inflammation without transmural involve- nose and throat should also be considered as extraintesti- ment, but extraintestinal manifestations of UC have also been nal involvement sites of IBD.
    [Show full text]
  • Pristiq (Desvenlafaxine Succinate) – First-Time Generic
    Pristiq® (desvenlafaxine succinate) – First-time generic • On March 1, 2017, Teva launched AB-rated generic versions of Pfizer’s Pristiq (desvenlafaxine succinate) 25 mg, 50 mg, and 100 mg extended-release tablets for the treatment of major depressive disorder. — Teva launched the 25 mg tablet with 180-day exclusivity. — In addition, Alembic/Breckenridge, Mylan, and West-Ward have launched AB-rated generic versions of Pristiq 50 mg and 100 mg extended-release tablets. — Greenstone’s launch plans for authorized generic versions of Pristiq 25 mg, 50 mg, and 100 mg tablets are pending. — Lupin and Sandoz received FDA approval of AB-rated generic versions of Pristiq 50 mg and 100 mg tablets on June 29, 2015. Lupin’s and Sandoz’s launch plans are pending. • Other serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder include desvenlafaxine fumarate, duloxetine, Fetzima™ (levomilnacipran), Khedezla™ (desvenlafaxine) , venlafaxine, and venlafaxine extended-release. • Pristiq and the other serotonin-norepinephrine reuptake inhibitors carry a boxed warning for suicidal thoughts and behaviors. • According to IMS Health data, the U.S. sales of Pristiq were approximately $883 million for the 12 months ending on December 31, 2016. optumrx.com OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com. All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners. This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.
    [Show full text]
  • Evidence-Based Practice Center Systematic Review Protocol
    Evidence-based Practice Center Systematic Review Protocol Project Title: Serum-Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias I. Background and Objectives for the Systematic Review Plasma cell dyscrasias (PCDs) are a spectrum of disorders characterized by the expansion of a population of monoclonal bone-marrow plasma cells that produce monoclonal immunoglobulins.1 At the benign end of the spectrum is monoclonal gammopathy of undetermined significance (MGUS), where the plasma-cell clone usually does not expand. Multiple myeloma (MM) is a plasma cell disorder at the malignant end of the spectrum and is characterized by the neoplastic proliferation of a clone of plasma cells in the bone marrow with resulting end-organ damage, including skeletal destruction (lytic bone lesions), hypercalcemia, anemia, and renal insufficiency. Whereas monoclonal plasma cells generally secrete intact immunoglobulin, in about 20 percent of patients with MM these cells only produce light-chain monoclonal proteins (i.e., light-chain multiple myeloma [LCMM], formerly known as Bence Jones myeloma) and in 3 percent of patients they secrete neither light- nor heavy-chain monoclonal proteins that are detectable by immunofixation (i.e., nonsecretory multiple myeloma [NSMM]).1 In two-thirds of patients with NSMM, a monoclonal protein can be identified by the serum-free light chain (SFLC) assay. Patients with LCMM develop complications related to tissue deposition of light chains, including amyloidosis. Amyloid light-chain (AL) amyloidosis is the most common form of systemic amyloidosis seen in the United States and is characterized by a relatively stable, slow-growing plasma-cell clone that secretes light-chain proteins that form Table 1: Diagnostic criteria and clinical course of selected plasma cell dyscrasias (PCDs)2 Disorder Disease Definition Clinical Course Monoclonal gammopathy of .
    [Show full text]
  • A New Classification for Septal Perforation and Effects of Treatment
    Braz J Otorhinolaryngol. 2019;85(6):716---723 Brazilian Journal of OTORHINOLARYNGOLOGY www.bjorl.org ORIGINAL ARTICLE A new classification for septal perforation and effects ଝ of treatment methods on quality of life a,∗ b a Emrah Sapmaz , Yuksel Toplu , Battal Tahsin Somuk a Gaziosmanpas¸a University Medical Faculty, Department of Otorhinolaryngology, Tokat, Turkey b Inonu University Medical Faculty, Department of Otorhinolaryngology, Malatya, Turkey Received 7 March 2018; accepted 6 June 2018 Available online 17 July 2018 KEYWORDS Abstract Septal perforation Introduction: Septal perforation is a condition characterized by loss of cartilage and/or bony Quality of life; structures along with the mucoperichondrium and mucoperiosteum lining them. The etiology Septal button includes a history of nasal surgery or trauma, nose picking, bilateral septal cauterization, overuse of nasal sprays, cocaine abuse, vasculitis, and malignancies. Objective: Comparison of quality of life in patients with septal perforation after conservative or surgical treatment, and a new approach for the determination of the diameter of the perforation from a different point of view. Methods: The diameter of septal perforation, total vertical diameter of septum, and horizontal diameter of the perforation were measured in a total of 34 patients. Nineteen of the patients underwent surgical septal perforation repair, and 15 of them received septal button application. The patients were asked to complete the Glasgow Benefit Inventory quality of life questionnaire. Results: The septal perforation successfully healed in 18 of 19 patients who underwent surgi- cal treatment. The quality of life scores were statistically significantly higher in the surgical treatment group when compared to the button group (p < 0.05).
    [Show full text]